Printer Friendly

BIOSPECIFICS ANNOUNCES EXPANSION OF CLINICAL TRIALS FOR OINTMENT

 BIOSPECIFICS ANNOUNCES EXPANSION OF CLINICAL TRIALS FOR OINTMENT
 LYNBROOK, N.Y., May 28 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that the clinical evaluation of the use of their Collagenase ointment in the treatment of deep second degree burns was being expanded to four additional burn centers. The initial clinical trials were done at Stonybrook University, N.Y., under the direction of Harry Soroff, M.D., chief of the burn unit.
 The results of that trial indicated a substantial savings in the time required to heal lesions treated with Collagenase as compared to the standard treatment. The company believes that this finding, when confirmed, should significantly increase the market for the ointment which is approved for use in burns.
 The expanded study is designed to confirm and further define the benefits to be expected.
 BioSpecifics produces and licenses pharmaceutical products for domestic and international sales. The company is also engaged in various stages of research, development, clinical testing and marketing of additional pharmaceutical products and therapeutically active molecules. The company's current principal product is its FDA-approved enzyme Collagenase ABC, used in topical applications for treatment of dermal ulcers and severely burned areas.
 -0- 5/28/92
 /CONTACT: Edwin Wegman, chairman of BioSpecifics, 516-593-7000; or Sam Witchel of Scharff, Witchel & Co., 212-983-1060, for BioSpecifics/
 (BSTC) CO: BioSpecifics Technologies Corp. ST: New York IN: MTC SU:


GK-SH -- NY038 -- 4698 05/28/92 11:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 28, 1992
Words:234
Previous Article:AT&T ADDS PRODUCTS TO EXHIBIT AS CONSUMER ELECTRONICS SHOW PREPARES TO OPEN TO GENERAL PUBLIC
Next Article:CLOTHESTIME TO ADDRESS AGGRESSIVE GROWTH STOCK CONFERENCE, JUNE 3
Topics:


Related Articles
BIOSPECIFICS TECHNOLOGIES RECEIVES CLINICAL TRIAL EXEMPTION FOR COLLAGENASE OINTMENT IN ENGLAND
RESEARCH TESTING OF COLLAGENASE ON PEYRONIE'S DISEASE PATIENTS SHOWS POSITIVE RESULTS
BIOSPECIFICS TECHNOLOGIES CORP. LICENSEE RECEIVES MARKETING APPROVAL OF COLLAGENASE OINTMENT IN INDIA
BIOSPECIFICS TECHNOLOGIES CORP.'S COLLAGENASE CHOSEN AS A PREFERRED TREATMENT OF PRESSURE SORES BY FEDERAL GOVERNMENT HEALTH AGENCY
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL COMPLETION OF NUCLEOLYSIN CLINICAL TRIAL IN ITALY
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL COMPLETION IN UNITED KINGDOM OF CLINICAL STUDY OF COLLAGENASE OINTMENT FOR TREATMENT OF PRESSURE...
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL ITALIAN CLINICAL TRIALS
BioSpecifics Announces Phase 2 Start of Dupuytren's Disease Study With Cordase(TM) Injectable Collagenase
BioSpecifics Technologies Corp. Notified by Nasdaq Listing Qualifications Panel That Its Shares Will Be Delisted; Trading to Start March 24, 2004 on...
BioSpecifics Announces Abbott Laboratories to Market Collagenase Santyl(R) Ointment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters